Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Yen Chang, Tianhao Song, Jane Monaco & Anastasia Ivanova. (2020) Futility stopping in clinical trials, optimality and practical considerations. Journal of Biopharmaceutical Statistics 30:6, pages 1050-1059.
Read now
Read now
Shixin Li, Hua Jin & Wanyi Chen. (2018) Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm. Communications in Statistics - Theory and Methods 47:22, pages 5626-5638.
Read now
Read now
Hayet Merabet, Ahlam Labdaoui & Pierre Druilhet. (2017) Bayesian prediction for two-stage sequential analysis in clinical trials. Communications in Statistics - Theory and Methods 46:19, pages 9807-9816.
Read now
Read now
Pierpaolo Brutti, Fulvio De Santis, Stefania Gubbiotti & Valeria Sambucini. (2016) Continuous endpoints in Bayesian two-stage designs. Journal of Biopharmaceutical Statistics 26:5, pages 966-977.
Read now
Read now
John A. Kairalla, Christopher S. Coffey, Mitchell A. Thomann, Ronald I. Shorr & Keith E. Muller. (2015) Adaptive designs for comparative effectiveness research trials. Clinical Research and Regulatory Affairs 32:1, pages 36-44.
Read now
Read now
James M. S. Wason. (2013) Reducing the average number of patients needed in a phase II trial through novel design. Clinical Research and Regulatory Affairs 30:4, pages 47-54.
Read now
Read now
Articles from other publishers (11)
Nina Wilson, Katie Biggs, Sarah Bowden, Julia Brown, Munyaradzi Dimairo, Laura Flight, Jamie Hall, Anna Hockaday, Thomas Jaki, Rachel Lowe, Caroline Murphy, Philip Pallmann, Mark A. Pilling, Claire Snowdon, Matthew R. Sydes, Sofía S. Villar, Christopher J. Weir, Jessica Welburn, Christina Yap, Rebecca Maier, Helen Hancock & James M. S. Wason. (2021) Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project. BMC Medicine 19:1.
Crossref
Crossref
Michael J. Grayling & Adrian P. Mander. (2021) Accounting for variation in the required sample size in the design of group-sequential trials. Contemporary Clinical Trials 107, pages 106459.
Crossref
Crossref
Maximilian Pilz, Kevin Kunzmann, Carolin Herrmann, Geraldine Rauch & Meinhard Kieser. (2021) Optimal planning of adaptive two‐stage designs. Statistics in Medicine 40:13, pages 3196-3213.
Crossref
Crossref
Munyaradzi Dimairo, Philip Pallmann, James Wason, Susan Todd, Thomas Jaki, Steven A. Julious, Adrian P. Mander, Christopher J. Weir, Franz Koenig, Marc K. Walton, Jon P. Nicholl, Elizabeth Coates, Katie Biggs, Toshimitsu Hamasaki, Michael A. Proschan, John A. Scott, Yuki Ando, Daniel Hind, Douglas G. Altman, Munyaradzi Dimairo, Toshimitsu Hamasaki, Susan Todd, Christopher J. Weir, Adrian P. Mander, James Wason, Franz Koenig, Steven A. Julious, Daniel Hind, Jon Nicholl, Douglas G. Altman, William J. Meurer, Christopher Cates, Matthew Sydes, Yannis Jemiai, Deborah Ashby, Christina Yap, Frank Waldron-Lynch, James Roger, Joan Marsh, Olivier Collignon, David J. Lawrence, Catey Bunce, Tom Parke, Gus Gazzard, Elizabeth Coates, Marc K. Walton, Sally Hopewell, Philip Pallmann, Thomas Jaki, Katie Biggs, Michael A. Proschan, John A. Scott & Yuki Ando. (2020) The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials 21:1.
Crossref
Crossref
Munyaradzi Dimairo, Philip Pallmann, James Wason, Susan Todd, Thomas Jaki, Steven A Julious, Adrian P Mander, Christopher J Weir, Franz Koenig, Marc K Walton, Jon P Nicholl, Elizabeth Coates, Katie Biggs, Toshimitsu Hamasaki, Michael A Proschan, John A Scott, Yuki Ando, Daniel Hind & Douglas G Altman. (2020) The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ, pages m115.
Crossref
Crossref
Kim May Lee, James Wason & Nigel Stallard. (2019) To add or not to add a new treatment arm to a multiarm study: A decision‐theoretic framework. Statistics in Medicine.
Crossref
Crossref
Tim Pickles, Robin Christensen, Lai-Shan Tam, Lee S Simon & Ernest H Choy. (2018) Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials. Rheumatology Advances in Practice 2:2.
Crossref
Crossref
Wei Jiang, Jonathan D. Mahnken, Jianghua He & Matthew S. Mayo. (2016) Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family. Pharmaceutical Statistics 15:6, pages 459-470.
Crossref
Crossref
Deli Wang, Lu Cui, Lanju Zhang & Bo Yang. 2016. New Developments in Statistical Modeling, Inference and Application. New Developments in Statistical Modeling, Inference and Application
121
147
.
James M. S. Wason. 2014. Developments in Statistical Evaluation of Clinical Trials. Developments in Statistical Evaluation of Clinical Trials
97
118
.
James M. S. WasonThomas Jaki. (2012) Optimal design of multi-arm multi-stage trials. Statistics in Medicine 31:30, pages 4269-4279.
Crossref
Crossref